sacituzumab govitecan
gilead sciences
['bcsm', 'breast', 'trodelvy']
data from 's and colleagues presented at #asco22 demonstrated that treatment with trodelvy reduced the risk of disease progression by 34% compared with chemo in patients with hr positive, her2-negative metastatic breast cancer #bcsm 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.